SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML
SELLAS Life Sciences Group, Inc. announced topline data from the Phase 2a study of SLS009 and provides an update on Phase 3 REGAL Study of GPS in AML. The REGAL Steering Committee met on March 22,...
Source: marketscreener.com